This transaction
This transferThe voting-rights ratio is the share of the votes exercisable at a shareholders’ meeting that will be held after this transaction.
Manufacture of over-the-counter drugs, including athlete's foot and acne treatments
An extraordinary loss is expected to be recognized in the fiscal year ending December 2026, but the amount is currently under review.
| Item | Details |
|---|---|
| Transaction name | This transfer |
| Counterparty name | 万全万特製薬（厦門）有限公司 |
| Name of the Subject Company | 江蘇小林製薬有限公司 |
| Business Description of the Subject Company | Manufacture of over-the-counter drugs, including athlete's foot and acne treatments |
| Location of the Subject Company | No. 8 Zhongdan Road, Hongqiao Town, Taixing City, Jiangsu Province, People's Republic of China |
| Capital Stock of the Subject Company | RMB 50 million (Kobayashi Pharmaceutical (China) Co., Ltd. plans to make a capital increase in September 2026) |
| Date of Establishment of the Subject Company | 9 July 2003 |
| Net Sales of the Subject Company | RMB 4 million (fiscal year ended December 2025) |
| Operating Profit of the Subject Company | Operating loss of RMB 13 million (fiscal year ended December 2025) |
| Net Income of the Subject Company | Net loss of RMB 15 million (fiscal year ended December 2025) |
| Net Assets of the Subject Company | Net assets of negative RMB 153 million (fiscal year ended December 2025) |
| Acquisition price | The transfer price is not disclosed due to the confidentiality obligations under the equity transfer agreement. |
| Voting rights ownership percentage | Before 100% → after 0% |
| Amount of extraordinary income (loss) | An extraordinary loss is expected to be recognized in the fiscal year ending December 2026, but the amount is currently under review. |
| Impact on Business Performance | An extraordinary loss is expected to be recognized in the fiscal year ending December 2026, but the amount is currently under review. |
| Date of board resolution | 6 August 2026 |
| Contract Date | Mid-August 2026 (scheduled) |
| Execution Date / Effective Date | End of October 2026 (予定) |
Items this document does not state (14)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Following a review of changes in China's pharmaceutical regulatory system and market environment, the Company's business portfolio, and Jiangsu Kobayashi Pharmaceutical's manufacturing and sales business, the Company determined that it could expand its over-the-counter drug business in China without owning its own manufacturing plant and concluded that transferring the equity interest was the best option. The Company also stated that the transfer will have no impact on Anmeru, which is currently sold in China, because it is not manufactured by Jiangsu Kobayashi Pharmaceutical, and that sales will continue.